BioMarin Pharmaceutical (BMRN) director Dere received 7,490 shares
Insider transactions reported
Willard H Dere (director at BioMarin Pharmaceutical Inc., BMRN) reported that they received 7,490 shares on Jun 2, 2026. After these transactions the filing shows 46,440 shares held directly.
- Reporting person
- Dere Willard H
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Grant or award (A) | Common Stock1 | +7,490 | - | - | 46,440 direct |
Holdings before and after
- Common Stock: 38,950 to 46,440 direct
Footnotes from the filing
- 1. Restricted stock units granted on June 2, 2026. Price not applicable.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Dere report in this BMRN Form 4?
Willard H Dere (director at BioMarin Pharmaceutical Inc., BMRN) reported that they received 7,490 shares on Jun 2, 2026. After these transactions the filing shows 46,440 shares held directly.
How many BMRN shares does Dere hold after this filing?
The filing shows 46,440 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for BMRN
Across the 25 sessions after earlier BMRN headlines, the stock closed higher 11 times and lower 14 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BMRN | SPY |
|---|---|---|---|
| May 21, 2026 | BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia | +7.8% | +0.2% |
| May 19, 2026 | Citigroup initiated coverage on BioMarin Pharmaceutical with a new price target | +0.3% | -0.7% |
| May 18, 2026 | BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | -4.1% | -0.1% |
| May 11, 2026 | Goldman resumed coverage on BioMarin Pharmaceutical with a new price target | -2.7% | +0.2% |
| May 5, 2026 | BioMarin Reports First Quarter 2026 Financial and Operating Results | -4.0% | +0.8% |
| May 4, 2026 | BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting | +2.6% | -0.4% |
Earlier insider filings at BMRN
- Jun 4, 2026Director Clark Ian T was granted 7,490 shares, increasing direct ownership by 107% to 14,490 units (SEC Form 4)
- Jun 4, 2026Director Bodem Barbara W. was granted 7,490 shares, increasing direct ownership by 55% to 21,045 units (SEC Form 4)
- Jun 4, 2026Director Anderson Elizabeth M was granted 7,490 shares, increasing direct ownership by 22% to 41,940 units (SEC Form 4)
- May 21, 2026EVP, Chief Commercial Officer Hubbard Cristin covered exercise/tax liability with 2,318 shares, decreasing direct ownership by 5% to 42,472 units (SEC Form 4)
- May 11, 2026EVP, Chief R&D Officer Friberg Gregory R sold $176,682 worth of shares (3,281 units at $53.85), decreasing direct ownership by 6% to 51,818 units (SEC Form 4)
Keep researching BMRN
- BMRN insider tradesEvery buy and sale reported by BioMarin Pharmaceutical Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- BMRN earnings historyPast BioMarin Pharmaceutical Inc. earnings releases, newest first.
- BMRN financial statementsRevenue, profit, cash flow and balance sheet from BioMarin Pharmaceutical Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 1999
Follow BMRN and get a push notification the moment its next story breaks.